T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma

Author:

Barsch MaryamORCID,Salié HenrikeORCID,Schlaak Alexandra EmiliaORCID,Zhang Zhen,Hess Moritz,Mayer Lena Sophie,Tauber Catrin,Otto-Mora Patricia,Ohtani Takuya,Nilsson TobiasORCID,Wischer Lara,Winkler Frances,Manne Sasikant,Rech Andrew,Schmitt-Graeff Annette,Bronsert Peter,Hofmann MaikeORCID,Neumann-Haefelin ChristophORCID,Boettler Tobias,Fichtner-Feigl Stefan,van Boemmel Florian,Berg ThomasORCID,Rimassa LorenzaORCID,Di Tommaso LucaORCID,Saeed AnwaarORCID,D’Alessio Antonio,Pinato David J.,Bettinger DominikORCID,Binder HaraldORCID,John Wherry E.,Schultheiss Michael,Thimme Robert,Bengsch BertramORCID

Publisher

Elsevier BV

Subject

Hepatology

Reference30 articles.

1. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

2. IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC);Finn;J Clin Oncol,2021

3. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma;Flecken;Hepatology,2014

4. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features;Sia;Gastroenterology,2017

5. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial;Finn;J Clin Oncol,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3